A vaccine for all mankind: Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet
In an interim analysis of a Phase III clinical trial, Sputnik V
showed
Efficacy of Sputnik V against COVID-19 was reported at 91.6%.
- Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
- Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8% and did not differ statistically from the 18-60 group.
Sputnik V provides full protection against severe cases of COVID-19.
To improve the performance of our website, show the most relevant news products and targeted advertising, we collect technical impersonal information about you, including through the tools of our partners. You can find a detailed description of how we use your data in our Privacy Policy. For a detailed description of the technologies, please see the Cookie and Automatic Logging Policy.
By clicking on the Accept & Close button, you provide your explicit consent to the processing of your data to achieve the above goal.
You can withdraw your consent using the method specified in the Privacy Policy.
Accept & Close
Sputnik International
TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load.
Share this article
TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/
Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation
As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes
First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., did not have antibodies at baseline: seronegative), as prior evidence suggested these patients were at greater risk. The primary clinical objective of th
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
A total of 510 patients enrolled
Events required to trigger interim superiority analysis accrued
Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021
LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) ERYTECH Pharma (Nasdaq & Euronext: ERYP),
a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer.
TRYbeCA-1, the pivotal Phase 3 clinical trial evaluating ERYTECH’s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has completed patient enrollment. A total of 510 patients participated in the trial, slightly above the target enrollment of 482 patients.